Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: ...

AI tools are fundamentally changing software development. Investing in foundational knowledge and deep expertise secures your ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

From someone who can’t yet be considered a veteran music fan, though has been to his fair share of gigs, bought countless band tees, and collected numerous records over the years, music discovery, ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...

Launched last year, social media platform UpScrolled has already amassed millions of global downloads. Today, the app sits at the top of several app store rankings in multiple countries, including the ...